Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hMPV + RSV mRNA vaccine
- Development stage
- Phase 2
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine candidate composed of messenger RNA (mRNA) sequences encoding surface antigens from both human metapneumovirus (hMPV) and respiratory syncytial virus (RSV), encapsulated in a lipid nanoparticle (LNP) formulation. The vaccine is designed to induce immunity against lower respiratory tract disease caused by either or both hMPV and RSV. The mechanism of action relies on translation of the mRNA into viral proteins (typically prefusion F proteins), eliciting neutralizing antibody and T cell immune responses. This combination vaccine is under investigation principally for use in adults aged 60 years and older, with study goals focusing on safety, immunogenicity, and dose selection[1][5].
- Brand names
- none
- Other names
- hMPV/RSV mRNA vaccineRSV/hMPV mRNA vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)HMPV F (Human metapneumovirus fusion protein)
Beyond the preview
Go deeper on hMPV + RSV mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hMPV + RSV mRNA vaccine.